Vincristine sulfate liposomal - Luye Pharma Group

Drug Profile

Vincristine sulfate liposomal - Luye Pharma Group

Alternative Names: LY 01609; Vincristine sulphate liposomal - Luye Pharma Group

Latest Information Update: 25 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Luye Pharma Group
  • Class Antineoplastics; Vinca alkaloids
  • Mechanism of Action Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Acute lymphoblastic leukaemia

Most Recent Events

  • 25 Jul 2016 Vincristine sulfate liposome is still in phase III trials for Acute lymphoblastic leukaemia (first-line therapy) in China (NCT02072785)
  • 11 Sep 2013 Biomarkers information updated
  • 01 Jun 2013 Phase-III clinical trials in Acute lymphoblastic leukaemia (first-line therapy) in China (IV-injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top